Challenges of vaccination and herd immunity in COVID‐19 and management strategies
Abstract Coronavirus disease 2019 (COVID‐19), the highly contagious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread worldwide with millions of cases and more than 5 million deaths to date. SARS‐CoV‐2 has caused serious damage all over the world with many countries experiencing the third or the fourth wave of the viral disease outbreaks, mainly due to the emergence of mutant variants. Those who unvaccinated remain most vulnerable to COVID‐19 and its variants. COVID‐19 vaccination, along with prevention strategies, is a critical measure to defense against the disease. COVID‐19 vaccination can reduce the spread of virus and help protect susceptible population. Although herd immunity might not be realized solely by vaccination, COVID‐19 vaccines have been proved to be effective in reducing the risk of severe disease, hospitalization, and even death. It is recommended that people get vaccinated as soon as they are eligible. This review summarizes the recent SARS‐CoV‐2 variants that brought challenges for vaccination and herd immunity and discusses promising management strategies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
The Clinical Respiratory Journal - 16(2022), 11, Seite 708-716 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jun She [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID‐19 |
|---|
| doi: |
10.1111/crj.13543 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ02186876X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ02186876X | ||
| 003 | DE-627 | ||
| 005 | 20230503075006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/crj.13543 |2 doi | |
| 035 | |a (DE-627)DOAJ02186876X | ||
| 035 | |a (DE-599)DOAJ1ca0a2a8c92a48609cea07be1f7665cb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC705-779 | |
| 100 | 0 | |a Jun She |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges of vaccination and herd immunity in COVID‐19 and management strategies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Coronavirus disease 2019 (COVID‐19), the highly contagious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread worldwide with millions of cases and more than 5 million deaths to date. SARS‐CoV‐2 has caused serious damage all over the world with many countries experiencing the third or the fourth wave of the viral disease outbreaks, mainly due to the emergence of mutant variants. Those who unvaccinated remain most vulnerable to COVID‐19 and its variants. COVID‐19 vaccination, along with prevention strategies, is a critical measure to defense against the disease. COVID‐19 vaccination can reduce the spread of virus and help protect susceptible population. Although herd immunity might not be realized solely by vaccination, COVID‐19 vaccines have been proved to be effective in reducing the risk of severe disease, hospitalization, and even death. It is recommended that people get vaccinated as soon as they are eligible. This review summarizes the recent SARS‐CoV‐2 variants that brought challenges for vaccination and herd immunity and discusses promising management strategies. | ||
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a herd immunity | |
| 650 | 4 | |a prevention | |
| 650 | 4 | |a SARS‐CoV‐2 | |
| 650 | 4 | |a vaccination | |
| 653 | 0 | |a Diseases of the respiratory system | |
| 700 | 0 | |a Dongni Hou |e verfasserin |4 aut | |
| 700 | 0 | |a Cuicui Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Jing Bi |e verfasserin |4 aut | |
| 700 | 0 | |a Yuanlin Song |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t The Clinical Respiratory Journal |d Wiley, 2022 |g 16(2022), 11, Seite 708-716 |w (DE-627)DOAJ078602963 |x 1752699X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:11 |g pages:708-716 |
| 856 | 4 | 0 | |u https://doi.org/10.1111/crj.13543 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/1ca0a2a8c92a48609cea07be1f7665cb |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1111/crj.13543 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1752-6981 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1752-699X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 11 |h 708-716 | ||